Trial Profile
A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2022
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Folic acid; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms RA-BEGIN
- Sponsors Eli Lilly and Company
- 22 Feb 2022 Results of an analysis assessing, whether Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and structural damage progression in patients with rheumatoid arthritis using two phase III studies (RA-BEAM and RA-BEGIN) published in the Annals of the Rheumatic Diseases
- 09 Nov 2021 Results of post-hoc analysis of 3 studies (RA-BEGIN (NCT01711359); RA-BEAM (NCT01710358) & RA-BEACON (NCT01721044)) assessing the relative importance of PROs on the Patient Global Assessment of Disease Activity (PtGA) and health-related quality of life (HRQoL) and whether these differ in patients with good disease control compared with those not in low disease activity (LDA) or remission in different patient populations, presented at the ACR Convergence 2021.
- 27 Oct 2021 Results (n=3770) assessing safety of baricitinib for the treatment of rheumatoid arthritis from long-term extension study and integrated database (NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT02265705, NCT01721044, NCT01721057, NCT01711359 and NCT01885078), published in the Annals of the Rheumatic Diseases.